• July sales reached $715k, up from $690k in June
• August delivered sales of $838k, a 17% increase on July
• Amazon USA sales grew 12% month-on-month in August

The Calmer Co. International Limited (ASX: CCO), a leading consumer packaged goods company specialising in kava and other natural products, has provided an update on July and August trading performance following the release of its FY25 Annual Report. The recently reported Full Year FY25 Results demonstrated a successful pivot to a leaner, more efficient cost base in H2 FY25, after strong growth in H1. This was driven by a 27% reduction in total expenses in H2 ($3.22M vs $4.43M in H1), with $800k lower advertising spend and significantly reduced people costs following the transition to the Acuity eCommerce platform. The Operating Loss was improved by 33% to $(1.56m) in H2 vs $(2.36m) in H1, as a result of tighter expense controls and early benefits from retail price increases in Coles and Woolworths that were introduced late in Q4. The company reported that July sales reached $715k, up from $690k in June, marking a fourth consecutive month of growth under the rebased model. August delivered sales of $838k, a 17% increase on July, returning the Company to an annualised sales run-rate of over $10m. Amazon USA sales grew from AU$192k in July to AU$214k in August, a 12% month-on-month increase, fueled by the first full month of sales for the new Taki Mai flavoured kava shots. This saw the Company's market share on Amazon increase to 7% of the US kava category on the platform, an increase from 3% in the prior year. Subscriptions now represent 28% of sales and organic search visibility up 674% YoY, reflecting strong brand loyalty.

Key Value Drivers for FY26 include scaling Amazon USA sales through product innovation and digital marketing, driving retail sales velocity across Coles and Woolworths stores in Australia, and expanding B2B ingredient sales into the US health and wellness market.